US 10233170
2,3-disubstituted pyridine compounds as TGF-beta inhibitors and methods of use
granted A61KA61K2039/505A61K31/4439
Quick answer
US patent 10233170 (2,3-disubstituted pyridine compounds as TGF-beta inhibitors and methods of use) held by Rigel Pharmaceuticals, Inc. expires Mon Mar 14 2039 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Rigel Pharmaceuticals, Inc.
- Grant date
- Tue Mar 19 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Mar 14 2039 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 6
- CPC classes
- A61K, A61K2039/505, A61K31/4439, A61K31/444, A61K31/517